ethyl 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate | 1204926-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: ethyl 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
• CAS: 1204926-19-1
• 化学式: C₉H₈FN₃O₂
• 分子量: 209.18
• InChiKey: MIWAQWDSRLXHSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.17h， 生成 lithium 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
  参考文献：
  名称：

  Novel Derivatives

  摘要：

  本发明涉及新颖的哌嗪衍生物；其制备方法；含有这些衍生物的药物组合物；以及利用这些衍生物在治疗中治疗阻断Ca v 2.2钙通道有益的疾病。

  公开号：

  US20100016330A1
• 作为产物：
  描述：

  β-(Diethylamino)-α-fluoropropenal 在 lithium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以64%的产率得到ethyl 6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxylate
  参考文献：
  名称：

  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

  摘要：

  Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC50's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).

  DOI：

  10.1016/j.bmcl.2019.04.008

文献信息

• Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives
  申请人：Convergence Pharmaceuticals Limited

  公开号：US08093249B2

  公开（公告）日：2012-01-10

  The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

  本发明涉及新型哌嗪衍生物；其制备方法；含有这些衍生物的药物组合物；以及利用这些衍生物治疗阻断Cav2.2钙通道对其有益的疾病的方法。
• Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
  申请人：Genentech, Inc.

  公开号：US10988478B1

  公开（公告）日：2021-04-27

  Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

  本文描述了式 0、式 I 和式 II 的化合物以及用作白细胞介素-1 受体相关激酶（IRAK4）抑制剂的方法。
• [EN] PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS<br/>[FR] DÉRIVÉS PYRAZOLO [1,5 A]PYRIMIDINE EN TANT QUE MODULATEURS D'IRAK 4
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017108723A3

  公开（公告）日：2017-07-27
• [EN] PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE PYRAZOLOCHLOROPHÉNYLE, COMPOSITIONS ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018166993A3

  公开（公告）日：2019-02-07
• PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES
  申请人：Convergence Pharmaceuticals Limited

  公开号：EP2313413A1

  公开（公告）日：2011-04-27